Onimaru Mitsuho, Yonemitsu Yoshikazu, Tanii Mitsugu, Nakagawa Kazunori, Masaki Ichiro, Okano Shinji, Ishibashi Hiroaki, Shirasuna Kanemitsu, Hasegawa Mamoru, Sueishi Katsuo
Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Circ Res. 2002 Nov 15;91(10):923-30. doi: 10.1161/01.res.0000043281.66969.32.
Hepatocyte growth factor (HGF) is a potent angiogenic polypeptide that stimulates angiogenesis. Transcriptional regulation of HGF, however, has not been fully defined, with the exception of the hypoxia-mediated downregulation in cultured cells. In the present study, we report that angiogenic growth factors, including HGF, were upregulated in a murine model of critical limb ischemia in vivo, a finding that was in conflict with previous in vitro data. Mice deficient in basic fibroblast growth factor-2 (FGF-2) showed reduced induction of HGF protein in ischemic muscles, and overexpression of FGF-2 via gene transfer stimulated endogenous HGF, irrespective of the presence of ischemia. In culture, FGF-2 rapidly stimulated HGF mRNA, and a sustained expression was evident in the time course in vascular smooth muscle cells and fibroblasts. FGF-2-mediated induction of HGF was fully dependent on the mitogen-activated protein kinase pathway yet was not affected by either hypoxia or a protein kinase A inhibitor. In the early expression, FGF-2 directly stimulated HGF mRNA without the requirement of new protein synthesis, whereas sustained induction of HGF in the later phase was partly mediated by platelet-derived growth factor-AA. Furthermore, in vivo overexpression of FGF-2 significantly improved the blood perfusion, and the effect was abolished by systemic blockade of HGF in ischemic limbs. This is the first demonstration of a regulational mechanism of HGF expression via FGF-2 that was independent of the presence of hypoxia. The harmonized therapeutic effects of FGF-2, accompanied with the activity of endogenous HGF, may provide a beneficial effect for the treatment of limb ischemia.
肝细胞生长因子(HGF)是一种刺激血管生成的强效血管生成多肽。然而,除了在培养细胞中缺氧介导的下调外,HGF的转录调控尚未完全明确。在本研究中,我们报告包括HGF在内的血管生成生长因子在体内严重肢体缺血小鼠模型中上调,这一发现与先前的体外数据相矛盾。缺乏碱性成纤维细胞生长因子-2(FGF-2)的小鼠在缺血肌肉中HGF蛋白的诱导减少,通过基因转移过表达FGF-2可刺激内源性HGF,无论是否存在缺血。在培养中,FGF-2迅速刺激HGF mRNA,并且在血管平滑肌细胞和成纤维细胞的时间进程中持续表达明显。FGF-2介导的HGF诱导完全依赖于丝裂原活化蛋白激酶途径,但不受缺氧或蛋白激酶A抑制剂的影响。在早期表达中,FGF-2直接刺激HGF mRNA,无需新蛋白质合成,而后期HGF的持续诱导部分由血小板衍生生长因子-AA介导。此外,FGF-2的体内过表达显著改善了血液灌注,并且缺血肢体中HGF的全身阻断消除了这种作用。这是首次证明通过FGF-2对HGF表达的调控机制独立于缺氧的存在。FGF-2的协同治疗作用与内源性HGF的活性一起,可能为肢体缺血的治疗提供有益效果。